CD44-Gal9 signaling is identified as a clinically relevant axis promoting tumor invasiveness and immune evasion in IDH1-mutant astrocytomas andTherapeutic inhibition of this interaction may represent a promising strategy to simultaneously attenuate tumor aggressiveness and reprogram the tumor microenvironment.
Abstract
IDH1-mutant grade 4 astrocytomas exhibit pronounced interactions with the tumor microenvironment that critically influence tumor progression. Tumor-associated microglia/macrophages (TAMs) are key mediators of these interactions, yet the molecular mechanisms governing tumor-TAM crosstalk remain incompletely understood. Here, we investigated the role of CD44-Galectin-9 (Gal9) signaling in patient-derived IDH1-mutant astrocytoma models.
scRNA-seq was performed on paired primary and recurrent high-grade astrocytomas to assess CD44 and Gal9 expression. CD44 was suppressed in tumor cells using shRNA-mediated knockdown, with or without exogenous Gal9. Conditioned media from control or CD44 knockdown tumor cells was applied to induced pluripotent stem cell-derived microglia (iMGs) to evaluate phagocytic activity. Tumor behavior was further assessed in 3D cerebral organoid co-culture models. Immunofluorescence analyses were used to examine spatial expression patterns of CD44 and Gal9.
scRNA-seq analysis revealed marked overexpression of CD44 in tumor cells, while Gal9 expression was predominantly associated with TAMs. CD44 knockdown significantly reduced tumor cell proliferation and invasion in vitro. Exogenous Gal9 enhanced proliferative and invasive behavior in control tumor cells, whereas CD44-deficient cells were unresponsive, indicating a CD44-dependent pro-tumorigenic effect of Gal9. Conditioned media from CD44 knockdown tumor cells increased microglial phagocytic activity, suggesting altered tumor-mediated immune modulation. In 3D cerebral organoid co-cultures, CD44 knockdown tumor cells exhibited reduced invasion and proliferation. Immunofluorescence revealed peritumoral enrichment of Gal9 expression in iMGs, which was diminished in CD44 knockdown samples, with CD44 and Gal9 expression showing a strong positive correlation across models.
Together, these data identify CD44-Gal9 signaling as a clinically relevant axis promoting tumor invasiveness and immune evasion in IDH1-mutant astrocytomas. Therapeutic inhibition of this interaction may represent a promising strategy to simultaneously attenuate tumor aggressiveness and reprogram the tumor microenvironment.
It is demonstrated that CDH11 knockdown and CDH22 overexpression notably suppressed the proliferation, migration and invasion of LGG cells, and such pro-tumor effects could be attenuated by CDH11 silencing or CDH22 overexpression.
This study delineates a novel CAF-driven immunosuppressive pathway in HCC, where CD147+ CAFs enhance tumor cell PD-L1 expression and susceptibility to immune checkpoint blockade via a TIMP2/MMP2/IL-6 axis.
Yi-Fei Wang, Bo-Wei Lv, Xiao-Jing Su et al.· Asia-Pacific Journal of Clin...· 0 citations
The multi-RAS inhibitor, daraxonrasib, has demonstrated a remarkable improvement in outcomes for patients with metastatic PDAC. Pre-clinical murine studies have shown that the durable effects of the pre-clinical multi-RAS inhibitor, RMC-7977, require an intact immune system including CD8+ T cells and cross-presen...
Sheela R. Damle, Nancy Liu, Xiu-Yun Jiang et al.· Cancer Research· 0 citations
It is demonstrated that PDCD10 loss promotes GBM neo-angiogenesis involving complementary paracrine and GSC-like plasticity mechanisms, highlighting PDCD10 as a potential therapeutic target to suppress neo-angiogenesis in GBM.
Zhong-Rong Chen, Zhen Chen, Xue Wan et al.· Cells· 0 citations
It is suggested that the SHMT2–lactate–CAF axis contributes to the metabolic–stromal regulation of T-cell exclusion and may represent a potential therapeutic target for improving the response of immune-excluded HNSCC to PD-1 blockade.
He-Lei Yan, Lu Wang, Zhen Li et al.· Cell Death & Disease· 0 citations
Findings suggest VEGFA–NRP1 signaling drives immune evasion in PDAC and identifies a therapeutic axis for reprogramming TAMs, providing a foundation for future combination immunotherapy strategies.
T. Lopez-Vidal, Jacob T. Mitchell, Kylie Belanger et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.